RESUMEN
Although the 3D structures of active and inactive cannabinoid receptors type 2 (CB2) are available, neither the X-ray crystal nor the cryo-EM structure of CB2-orthosteric ligand-modulator has been resolved, prohibiting the drug discovery and development of CB2 allosteric modulators (AMs). In the present work, we mainly focused on investigating the potential allosteric binding site(s) of CB2. We applied different algorithms or tools to predict the potential allosteric binding sites of CB2 with the existing agonists. Seven potential allosteric sites can be observed for either CB2-CP55940 or CB2-WIN 55,212-2 complex, among which sites B, C, G and K are supported by the reported 3D structures of Class A GPCRs coupled with AMs. Applying our novel algorithm toolset-MCCS, we docked three known AMs of CB2 including Ec2la (C-2), trans-ß-caryophyllene (TBC) and cannabidiol (CBD) to each site for further comparisons and quantified the potential binding residues in each allosteric binding site. Sequentially, we selected the most promising binding pose of C-2 in five allosteric sites to conduct the molecular dynamics (MD) simulations. Based on the results of docking studies and MD simulations, we suggest that site H is the most promising allosteric binding site. We plan to conduct bio-assay validations in the future.
Asunto(s)
Sitio Alostérico , Sitios de Unión , Moduladores de Receptores de Cannabinoides/química , Diseño de Fármacos , Modelos Moleculares , Receptor Cannabinoide CB2/química , Regulación Alostérica , Moduladores de Receptores de Cannabinoides/farmacología , Humanos , Ligandos , Conformación Molecular , Simulación del Acoplamiento Molecular , Simulación de Dinámica Molecular , Estructura Molecular , Unión Proteica , Relación Estructura-Actividad Cuantitativa , Receptor Cannabinoide CB2/metabolismoRESUMEN
Δ9-tetrahydrocannabinol (Δ9-THC), the main active ingredient of Cannabis sativa (marijuana), interacts with the human brain cannabinoid (CB1) receptor and mimics pharmacological effects of endocannabinoids (eCBs) like N-arachidonylethanolamide (AEA). Due to its flexible nature of AEA structure with more than 15 rotatable bonds, establishing its binding mode to the CB1 receptor is elusive. The aim of the present study was to explore possible binding conformations of AEA within the binding pocket of the CB1 receptor confirmed in the recently available X-ray crystal structures of the CB1 receptor and predict essential AEA binding domains. We performed long time molecular dynamics (MD) simulations of plausible AEA docking poses until its receptor binding interactions became optimally established. Our simulation results revealed that AEA favors to bind to the hydrophobic channel (HC) of the CB1 receptor, suggesting that HC holds essential significance in AEA binding to the CB1 receptor. Our results also suggest that the Helix 2 (H2)/H3 region of the CB1 receptor is an AEA binding subsite privileged over the H7 region.
Asunto(s)
Ácidos Araquidónicos/química , Endocannabinoides/química , Alcamidas Poliinsaturadas/química , Receptor Cannabinoide CB1/ultraestructura , Animales , Ácidos Araquidónicos/metabolismo , Encéfalo/metabolismo , Moduladores de Receptores de Cannabinoides/química , Cannabinoides/farmacología , Endocannabinoides/metabolismo , Endocannabinoides/farmacología , Humanos , Simulación del Acoplamiento Molecular/métodos , Simulación de Dinámica Molecular , Alcamidas Poliinsaturadas/metabolismo , Conformación Proteica , Dominios y Motivos de Interacción de Proteínas/fisiología , Receptor Cannabinoide CB1/química , Receptor Cannabinoide CB1/metabolismoRESUMEN
The rapidly changing landscape of cannabis in terms of availability, potency, and routes of administration, as well as the decrease in risk perception and changing norms, have contributed to an increase in the popularity of cannabis. Cannabis use is associated with a poorer recovery from a psychotic disorder, increasing the risk of relapse, rehospitalization, and lower social functioning. Data are mixed regarding cannabis use as a component cause of psychosis in people at risk for psychotic disorder. Care providers, parents, and schools must educate youth and adolescents about the risks of cannabis use.
Asunto(s)
Moduladores de Receptores de Cannabinoides , Uso de la Marihuana , Trastornos Psicóticos , Esquizofrenia , Adolescente , Moduladores de Receptores de Cannabinoides/administración & dosificación , Moduladores de Receptores de Cannabinoides/efectos adversos , Moduladores de Receptores de Cannabinoides/química , Moduladores de Receptores de Cannabinoides/provisión & distribución , Niño , Humanos , Uso de la Marihuana/efectos adversos , Uso de la Marihuana/epidemiología , Trastornos Psicóticos/epidemiología , Trastornos Psicóticos/etiología , Esquizofrenia/epidemiología , Esquizofrenia/etiologíaRESUMEN
MAIN CONCLUSION: Phytochemicals and secondary metabolites able to interact with the endocannabinoid system (Cannabimimetics) have been recently described in a broad range of plants and fruits. These findings can open new alternative avenues to explore for the development of novel therapeutic compounds. The cannabinoids regulate many physiological and pathological functions in both animals and plants. Cannabis sativa is the main plant that produces phytocannabinoids inside resins capable to defend the plant from the aggression of parasites and herbivores. Animals produce anandamide and 2-arachidonoyl glycerol, which thanks to binding with main receptors such as type-1 cannabinoid receptor (CB1R) and the type-2 cannabinoid receptor (CB2R) are involved in inflammation processes and several brain functions. Endogenous cannabinoids, enzymes for synthesis and degradation of cannabinoids, and CB1R and CB2R constitute the endocannabinoid system (ECS). Other plants can produce cannabinoid-like molecules such as perrottetinene extracted from Radula perrottetii, or anandamide and 2-arachidonoyl glycerol extracted from some bryophytes. Moreover, several other secondary metabolites can also interact with the ECS of animals and take the name of cannabimimetics. These phytoextracts not derived from Cannabis sativa can act as receptor agonists or antagonist, or enzyme inhibitors of ECS and can be involved in the inflammation, oxidative stress, cancer, and neuroprotection. Finally, given the evolutionary heterogeneity of the cannabimimetic plants, some authors speculated on the fascinating thesis of the evolutionary convergence between plants and animals regarding biological functions of ECS. The review aims to provide a critical and complete assessment of the botanical, chemical and therapeutic aspects of cannabimimetic plants to evaluate their spread in the world and medicinal potentiality.
Asunto(s)
Moduladores de Receptores de Cannabinoides/farmacología , Endocannabinoides/farmacología , Fitoquímicos/farmacología , Plantas/química , Animales , Ácidos Araquidónicos/química , Ácidos Araquidónicos/farmacología , Evolución Biológica , Agonistas de Receptores de Cannabinoides/química , Agonistas de Receptores de Cannabinoides/farmacología , Moduladores de Receptores de Cannabinoides/química , Cannabinoides/química , Cannabinoides/farmacología , Cannabis/química , Cannabis/genética , Cannabis/metabolismo , Dronabinol/análogos & derivados , Dronabinol/química , Dronabinol/farmacología , Endocannabinoides/química , Frutas/química , Frutas/genética , Frutas/metabolismo , Humanos , Fitoquímicos/química , Fitoquímicos/uso terapéutico , Plantas/genética , Plantas/metabolismo , Alcamidas Poliinsaturadas/química , Alcamidas Poliinsaturadas/farmacología , Receptores de Cannabinoides/metabolismoRESUMEN
The endocannabinoid system plays an important role in the pathophysiology of various neurological disorders, such as anxiety, depression, neurodegenerative diseases, and schizophrenia; however, little information is available on the coupling of the endocannabinoid system with the monoaminergic systems in the brain. In the present study, we tested four endocannabinoids and two anandamide analogs for inhibition of recombinant human MAO-A and -B (monoamine oxidase). Virodhamine inhibited both MAO-A and -B (IC50 values of 38.70 and 0.71⯵M, respectively) with â¼55-fold greater inhibition of MAO-B. Two other endocannabinoids (noladin ether and anandamide) also showed good inhibition of MAO-B with IC50 values of 18.18 and 39.98⯵M, respectively. Virodhamine was further evaluated for kinetic characteristics and mechanism of inhibition of human MAO-B. Virodhamine inhibited MAO-B (Ki value of 0.258⯱â¯0.037⯵M) through a mixed mechanism/irreversible binding and showed a time-dependent irreversible mechanism. Treatment of Neuroscreen-1 (NS-1) cells with virodhamine produced significant inhibition of MAO activity. This observation confirms potential uptake of virodhamine by neuronal cells. A molecular modeling study of virodhamine with MAO-B and its cofactor flavin adenine dinucleotide (FAD) predicted virodhamine's terminal -NH2 group to be positioned near the N5 position of FAD, but for docking to MAO-A, virodhamine's terminal -NH2 group was far away (â¼6.52â¯Å) from the N5 position of FAD, and encountered bad contacts with nearby water molecules. This difference could explain virodhamine's higher potency and preference for MAO-B. The binding free energies for the computationally-predicted poses also showed that virodhamine was selective for MAO-B. These findings suggest potential therapeutic applications of virodhamine for the treatment of neurological disorders.
Asunto(s)
Moduladores de Receptores de Cannabinoides/metabolismo , Cannabinoides/metabolismo , Endocannabinoides/metabolismo , Inhibidores de la Monoaminooxidasa/metabolismo , Monoaminooxidasa/metabolismo , Animales , Moduladores de Receptores de Cannabinoides/química , Moduladores de Receptores de Cannabinoides/farmacología , Cannabinoides/química , Cannabinoides/farmacología , Endocannabinoides/química , Endocannabinoides/farmacología , Humanos , Simulación del Acoplamiento Molecular/métodos , Inhibidores de la Monoaminooxidasa/química , Inhibidores de la Monoaminooxidasa/farmacología , Células PC12 , RatasRESUMEN
Also expressed in various peripheral tissues, the type-1 cannabinoid receptor (CB1R) is the predominant G protein-coupled receptor (GPCR) in brain, where it is responsible for retrograde control of neurotransmitter release. Cellular signaling mediated by CB1R is involved in numerous physiological processes, and pharmacological CB1R modulation is considered a tenable therapeutic approach for diseases ranging from substance-use disorders and glaucoma to metabolic syndrome. Despite the design and synthesis of a variety of bioactive small molecules targeted to the CB1R orthosteric ligand-binding site, the potential of CB1R as a therapeutic GPCR has been largely unrealized due to adverse events associated with typical orthosteric CB1R agonists and antagonists/inverse agonists. Modulation of CB1R-mediated signal transmission by targeting alternative allosteric ligand-binding site(s) on the receptor has garnered interest as a potentially safer and more effective therapeutic modality. This chapter highlights the design and synthesis of novel, pharmacologically active CB1R allosteric modulators and emphasizes how their molecular properties and the positive and negative allosteric control they exert can lead to improved CB1R-targeted pharmacotherapeutics, as well as designer covalent probes that can be used to map CB1R allosteric binding domains and inform structure-based drug design.
Asunto(s)
Moduladores de Receptores de Cannabinoides/farmacología , Receptor Cannabinoide CB1/fisiología , Regulación Alostérica , Sitio Alostérico , Animales , Moduladores de Receptores de Cannabinoides/química , Evaluación Preclínica de Medicamentos , Humanos , Ligandos , Unión ProteicaRESUMEN
The cannabinoid type 1 and 2 G-protein-coupled receptors are currently important pharmacological targets with significant drug discovery potential. These receptors have been shown to display functional selectivity or biased agonism, a property currently thought to have substantial therapeutic potential. Although recent advances in crystallization techniques have provided a wealth of structural information about this important class of membrane-embedded proteins, these structures lack dynamical information. In order to fully understand the interplay of structure and function for this important class of proteins, complementary techniques that address the dynamical aspects of their function are required such as NMR as well as a variety of other spectroscopies. Complimentary to these experimental approaches is molecular dynamics, which has been effectively used to help unravel, at the atomic level, the dynamics of ligand binding and activation of these membrane-bound receptors. Here, we discuss and present several representative examples of the application of molecular dynamics simulations to the understanding of the signatures of ligand-binding and -biased signaling at the cannabinoid type 1 and 2 receptors.
Asunto(s)
Simulación de Dinámica Molecular , Receptores de Cannabinoides/química , Animales , Moduladores de Receptores de Cannabinoides/química , Cannabinoides/química , Humanos , Ligandos , Membrana Dobles de Lípidos , Fosfatidilcolinas/química , Unión Proteica , Transducción de SeñalRESUMEN
Cannabidiol (CBD) is a phytocannabinoid with multiple pharmacological effects and several potential therapeutic properties. Its low oral bioavailability, however, can limit its clinical use. Preliminary results indicate that fluorination of the CBD molecule increases its pharmacological potency. Here, we investigated whether HUF-101 (3, 10, and 30mg/kg), a fluorinated CBD analogue, would induce antinociceptive effects. HUF-101 effects were compared to those induced by CBD (10, 30, and 90mg/kg) and the cannabinoid CB1/2 receptor agonist WIN55,212-2 (1, 3, and 5mg/kg). These drugs were tested in male Swiss mice submitted to the following models predictive to antinociceptive drugs: hot plate, acetic acid-induced writhing, and carrageenan-induced inflammatory hyperalgesia. To evaluate the involvement of CB1 and CB2 receptors in HUF-101 and CBD effects, mice received the CB1 receptor antagonist AM251 (1 or 3mg/kg) or the CB2 receptor antagonist AM630 (1 or 3mg/kg) 30min before HUF-101, CBD, or WIN55,212-2. In the hot plate test, HUF-101 (30mg/kg) and WIN55,212-2 (5mg/kg) induced antinociceptive effects, which were attenuated by the pretreatment with AM251 and AM630. In the abdominal writhing test, CBD (30 and 90mg/kg), HUF-101 (30mg/kg), and WIN55,212-2 (3 and 5mg/kg) induced antinociceptive effects indicated by a reduction in the number of writhing. Whereas the pretreatment with AM630 did not mitigate the effects induced by any drug in this test, the pretreatment with AM251 attenuated the effect caused by WIN55,212-2. In the carrageenan-induced hyperalgesia test, CBD (30 and 90mg/kg), HUF-101 (3, 10 and 30mg/kg) and WIN55,212-2 (1mg/kg) decreased the intensity of mechanical hyperalgesia measured by the electronic von Frey method. The effects of all compounds were attenuated by the pretreatment with AM251 and AM630. Additionally, we evaluated whether HUF-101 would induce the classic cannabinoid CB1 receptor-mediated tetrad (hypolocomotion, catalepsy, hypothermia, and antinociception). Unlike WIN55,212-2, CBD and HUF-101 did not induce the cannabinoid tetrad. These findings show that HUF-101 produced antinociceptive effects at lower doses than CBD, indicating that the addition of fluoride improved its pharmacological profile. Furthermore, some of the antinociceptive effects of CBD and HUF-101 effects seem to involve the activation of CB1 and CB2 receptors.
Asunto(s)
Analgésicos/farmacología , Cannabidiol/análogos & derivados , Moduladores de Receptores de Cannabinoides/farmacología , Analgésicos/química , Animales , Benzoxazinas/farmacología , Cannabidiol/química , Cannabidiol/farmacología , Moduladores de Receptores de Cannabinoides/química , Modelos Animales de Enfermedad , Relación Dosis-Respuesta a Droga , Halogenación , Indoles/farmacología , Masculino , Ratones , Morfolinas/farmacología , Naftalenos/farmacología , Dolor Nociceptivo/tratamiento farmacológico , Dolor Nociceptivo/metabolismo , Piperidinas/farmacología , Pirazoles/farmacología , Receptor Cannabinoide CB1/agonistas , Receptor Cannabinoide CB1/antagonistas & inhibidores , Receptor Cannabinoide CB1/metabolismo , Receptor Cannabinoide CB2/agonistas , Receptor Cannabinoide CB2/antagonistas & inhibidores , Receptor Cannabinoide CB2/metabolismoRESUMEN
Cannabimimetics (commonly referred to as synthetic cannabinoids), a group of compounds encompassing a wide range of chemical structures, have been developed by scientists with the hope of achieving selectivity toward one or the other of the cannabinoid receptors CB1 and CB2. The goal was to have compounds that could possess high therapeutic activity without many side effects. However, underground laboratories have used the information generated by the scientific community to develop these compounds for illicit use as marijuana substitutes. This chapter reviews the different classes of these "synthetic cannabinoids" with particular emphasis on the methods used for their identification in the herbal products with which they are mixed and identification of their metabolites in biological specimens.
Asunto(s)
Cannabinoides/farmacología , Receptor Cannabinoide CB1/efectos de los fármacos , Receptor Cannabinoide CB2/efectos de los fármacos , Animales , Moduladores de Receptores de Cannabinoides/análisis , Moduladores de Receptores de Cannabinoides/química , Moduladores de Receptores de Cannabinoides/farmacología , Cannabinoides/análisis , Cannabinoides/química , Drogas de Diseño/análisis , Drogas de Diseño/química , Drogas de Diseño/farmacología , Diseño de Fármacos , Humanos , Receptor Cannabinoide CB1/metabolismo , Receptor Cannabinoide CB2/metabolismoRESUMEN
An accumulating body of evidence suggests that endocannabinoids and cannabinoid receptors type 1 and 2 (CB(1), CB(2)) play a significant role in physiologic and pathologic processes, including cognitive and immune functions. While the addictive properties of marijuana, an extract from the Cannabis plant, are well recognized, there is growing appreciation of the therapeutic potential of cannabinoids in multiple pathologic conditions involving chronic inflammation (inflammatory bowel disease, arthritis, autoimmune disorders, multiple sclerosis, HIV-1 infection, stroke, Alzheimer's disease to name a few), mainly mediated by CB(2) activation. Development of CB(2) agonists as therapeutic agents has been hampered by the complexity of their intracellular signaling, relative paucity of highly selective compounds and insufficient data regarding end effects in the target cells and organs. This review attempts to summarize recent advances in studies of CB(2) activation in the setting of neuroinflammation, immunomodulation and HIV-1 infection.
Asunto(s)
Moduladores de Receptores de Cannabinoides/uso terapéutico , Inmunomodulación/inmunología , Neuronas/inmunología , Receptor Cannabinoide CB2/fisiología , Secuencia de Aminoácidos , Animales , Moduladores de Receptores de Cannabinoides/química , Moduladores de Receptores de Cannabinoides/farmacología , Infecciones por VIH/inmunología , Infecciones por VIH/metabolismo , Infecciones por VIH/patología , Humanos , Inmunomodulación/efectos de los fármacos , Inflamación/tratamiento farmacológico , Inflamación/inmunología , Inflamación/metabolismo , Marihuana Medicinal/química , Marihuana Medicinal/farmacología , Marihuana Medicinal/uso terapéutico , Datos de Secuencia Molecular , Neuronas/efectos de los fármacos , Neuronas/patología , Receptor Cannabinoide CB2/agonistas , Receptor Cannabinoide CB2/genéticaRESUMEN
Nowadays, the endocannabinoid-regulated processes are in the focus of interest, among others, for the treatment of stress-related disorders. In this minireview, we attempt to give some possible explanations for the conflicting results of the cannabinoidergic regulation of the hypothalamo-pituitary-adrenocortical (HPA) axis and related disorders, drawing attention to the complexity of the endocannabinoid system. The endocannabinoid system is a part of an intricate network of lipid pathways and consists of the cannabinoid receptors, their endogenous ligands, and the enzymes catalyzing their formation and degradation. The stress research is focused almost exclusively on the anandamide and 2-arachidonyl glycerol, and the cannabinoid 1 receptor. However, physiological, pathological, and pharmacological perturbations of the interconnected lipid pathways have a profound effect on the regulation of the endocannabinoid signaling system. For example, diet may substantially influence the lipid composition of the body. Recent studies have indicated that beside cannabinoid 1 receptor, the endocannabinoids may act on the cannabinoid 2, peroxisome proliferator-activated, and transient receptor potential of vanilloid type-1 receptors, too. All of these receptors are implicated in the development of stress-related disorders. However, it has to be mentioned that degradation of the endocannabinoids may result in the production of active compounds as well. Since endocannabinoids have a widespread distribution in the body, they may influence a phenomenon at several points. Different effects (stimulatory or inhibitory) at different levels of endocannabinoids (e.g. hypothalamus, hypophysis, adrenal gland in the case of HPA axis) may explain some of their unequivocal results.
Asunto(s)
Moduladores de Receptores de Cannabinoides/química , Moduladores de Receptores de Cannabinoides/metabolismo , Endocannabinoides , Estrés Fisiológico/fisiología , Estrés Psicológico/metabolismo , Estrés Psicológico/fisiopatología , Animales , Química Encefálica/fisiología , Humanos , Receptores de Cannabinoides/metabolismoRESUMEN
In vivo endocannabinoid (EC) microdialysis has only seldom been performed, mostly in rodent brain tissue. Low solubility in aqueous media, adsorption to surfaces, and instability with co-present human serum albumin (HSA) are the major obstacles in EC microdialysis. The addition of hydroxypropyl-ß-cyclodextrine (HPCD) to the perfusion fluid has been previously described to facilitate lipid microdialysis, but the general biophysical properties of HPCD, especially with respect to peripheral EC microdialysis, have not been described before. We report on the characterization of EC microdialysis using an in vitro system using Ringer's solution with 10% HPCD as the perfusion fluid and with fatty acid-free HSA as the matrix fluid. The endocannabinoids anandamide (AEA) and 2-arachidonoyl glycerol (2AG) were measured using LC-MS/MS. AEA was stable in the perfusion and matrix fluids, whereas 2AG was only stable in the perfusion fluid. In the matrix fluid, 2AG underwent rapid isomerization to 1-arachidonoyl glycerol. A relative recovery of 3.5% for AEA was found with 10% HPCD in the perfusion fluid and a flow rate of 1 µL/min. For 2AG, a similar relative recovery of 3.5% was estimated. Since 2AG was found unstable in the matrix fluid, a reliable calculation of the relative recovery rates was not possible. Delivery and recovery experiments revealed unequal inward and outward EC transport across the microdialysis membrane. Contrary to usual microdialysis findings, we observed increasing recovery rates for AEA with increasing flow rates. Long equilibration times of several hours were necessary to obtain constant relative recovery rates. In a proof-of-concept study in humans, we collected AEA from subcutaneous abdominal adipose tissue employing the described methodology. Our study suggests that the microdialysis technique is not suitable for the exact quantification of tissue EC concentrations, but it allows for their rough estimation.
Asunto(s)
Grasa Abdominal/química , Moduladores de Receptores de Cannabinoides/química , Endocannabinoides , Microdiálisis/métodos , Adsorción , Cromatografía Liquida , Humanos , Microdiálisis/instrumentación , Espectrometría de Masas en TándemRESUMEN
Endocannabinoids have been implicated in cancer development and cause heterogenous effects in tumor cells, by inducing apoptosis, reducing migration, causing anti-angiogenic activity and alterations in the cell cycle resulting in growth arrest. Recently, several novel amides of fatty acids that are structurally related to endocannabinoids have been isolated from mammalian sources, although the functions of these fatty amides are not well studied. One group of these novel fatty acid amides are the N-acyl taurines (fatty acids conjugated to the amino acid taurine). This study examined if N-acyl taurines, specifically N-arachidonoyl taurine and N-oleoyl taurine could function in a similar way to endocannabinoids and result in cell cycle alterations or growth arrest in the human prostate adenocarcinoma cell line PC-3. PC-3 cells were treated with various concentrations of N-arachidonoyl taurine and N-oleoyl taurine and cell proliferation and viability was measured using resazurin and colony formation assays. Effects of N-acyl taurines on the cell cycle was measured using FACS analysis. Treatment with N-arachidonoyl taurine and N-oleoyl taurine resulted in a significant reduction in proliferation of PC-3 cells, even at concentrations as low as 1 µM. Treatment with N-oleoyl taurine resulted in an increased number of cells in the subG1 population, suggesting apoptosis, and a lower number of cells in S-phase of the cell cycle. In summary, our results show that novel biologically active lipids, the N-acyl taurines, result in reduced proliferation in PC-3 cells.
Asunto(s)
Adenocarcinoma/tratamiento farmacológico , Ácidos Araquidónicos/farmacología , Próstata/efectos de los fármacos , Neoplasias de la Próstata/tratamiento farmacológico , Taurina/análogos & derivados , Adenocarcinoma/patología , Apoptosis/efectos de los fármacos , Ácidos Araquidónicos/química , Moduladores de Receptores de Cannabinoides/química , Moduladores de Receptores de Cannabinoides/farmacología , Recuento de Células , Ciclo Celular/efectos de los fármacos , Línea Celular Tumoral , Proliferación Celular/efectos de los fármacos , Supervivencia Celular/efectos de los fármacos , Relación Dosis-Respuesta a Droga , Citometría de Flujo , Humanos , Masculino , Oxazinas , Próstata/patología , Neoplasias de la Próstata/patología , Taurina/química , Taurina/farmacología , XantenosRESUMEN
INTRODUCTION: Perinatal asphyxia is the most frequent cause of neonatal brain injury and, despite advances in neonatology, it has not been possible to reduce its incidence. This is due to the difficulty to diagnose with precision the presence and onset of hypoxia and also to the existence of a limited period of time in which rescue strategies are effective. Thus, it is necessary to find out new and more effective therapeutic strategies, appearing the use of cannabinoids as a promising one. DEVELOPMENT: The endocannabinoid system modulates a wide range of physiological processes in mammals, being its participation in the retrograde system of signaling one of the most important, so it has been considered as an endogenous neuroprotective system. In experimental models of perinatal asphyxia, modulation of the endocannabinoid system through the administration of synthetic cannabinoids and endocannabinoids has demonstrated neuroprotective effects both in vitro and in vivo, by inhibition the intracellular calcium influx, decreasing the release of glutamate and cytokines, diminishing the inflammatory response and leading hypothermia. Moreover, it seems to play an important role in the development of the central nervous system, as it appears in the fetal period since the beginning. CONCLUSION: Modulation of the endocannabinoid system appears as a novel therapeutic strategy against neonatal hypoxic-ischemic brain injury.
Asunto(s)
Asfixia Neonatal/tratamiento farmacológico , Moduladores de Receptores de Cannabinoides/uso terapéutico , Endocannabinoides , Hipoxia-Isquemia Encefálica/tratamiento farmacológico , Fármacos Neuroprotectores/uso terapéutico , Asfixia Neonatal/fisiopatología , Moduladores de Receptores de Cannabinoides/química , Humanos , Hipoxia-Isquemia Encefálica/fisiopatología , Recién Nacido , Estructura MolecularRESUMEN
Omega-3 (n-3) fatty acids inhibit breast and prostate cancer cell growth. We previously showed that N-acylethanolamine derivatives of n-3 (n-3-NAE) are endocannabinoids, which regulate cancer cell proliferation. These n-3-NAE are synthesised in certain cells/tissues, after supplementing with fatty acids, however, no one has assessed whether and to what extent this occurs in cancer cells. We determined levels of endogenous n-3-NAEs in hormone sensitive and insensitive prostate and breast cancer cells and subsequent effects on other endocannabinoids (anandamide and 2-arachidonoylglycerol), before and after supplementing with DHA and EPA fatty acids, using HPLC tandem mass spectrometry. This is the first study reporting that n-3-NAEs are synthesised from their parent n-3 fatty acids in cancer cells, regardless of tumour type, hormone status or the presence of fatty acid amide hydrolase. This could have important implications for the use of n-3 fatty acids as therapeutic agents in breast and prostate cancers expressing cannabinoid receptors.
Asunto(s)
Neoplasias de la Mama/metabolismo , Moduladores de Receptores de Cannabinoides/biosíntesis , Etanolaminas/metabolismo , Ácidos Grasos Omega-3/metabolismo , Neoplasias de la Próstata/metabolismo , Amidohidrolasas/antagonistas & inhibidores , Amidohidrolasas/metabolismo , Moduladores de Receptores de Cannabinoides/química , Línea Celular Tumoral , Femenino , Humanos , Masculino , Espectrometría de Masas en TándemRESUMEN
The endocannabinoids anandamide (arachidonoyl ethanolamide, AEA) and 2-arachidonoyl glycerol (2AG) are physiologically occurring, biologically active compounds on CB(1) and CB(2) receptors with multiple physiological functions. AEA and 2AG have been identified and quantified in many mammalian biological fluids and tissues, such as human plasma, adipocytes, tissues and tissue microdialysates, at concentrations in the picomolar-to-nanomolar range under basal conditions. In this article, recently published chromatographic and mass spectrometric analytical methods, i.e., HPLC with fluorescence or ultraviolet detection, LC-MS, LC-MS/MS, GC-MS and GC-MS/MS, are reviewed and discussed, notably from the quantitative point of view. We focus on and emphasize the particular importance of blood sampling, sample storage and work-up including solvent and solid-phase extraction and derivatization procedures, matrix-effects, and stability of analytes. As 2AG spontaneously isomerizes to its CB(1)/CB(2) receptors biologically inactive 1-arachidonoyl glycerol (1AG) by acyl migration, this phenomenon and its particular importance for accurate quantification of 2AG are discussed in detail. Due to the electrical neutrality of AEA and 2AG their solvent extraction by toluene offers the least matrix-effect and minimum isomerization. LC-MS/MS is the most frequently used analytical technique for AEA and 2AG. At present, the utility of the GC-MS/MS methodology seems to be limited to AEA measurement in human plasma, bronchoalveolar liquid (BAL) and microdialysate samples. Despite great instrumental advances in the LC-MS/MS methodology, sampling and sample treatment remains one of the most crucial analytical steps in 2AG analysis. Extension of the LC-MS/MS methodology, for instance to microdialysate and BAL samples from clinical studies, is a big analytical challenge in endocannabinoid analysis in clinical settings. Currently available LC-MS/MS and GC-MS/MS methods should be useful to investigate the metabolism of AEA and 2AG beyond hydrolysis, i.e., by ß- and ω-oxidation pathways.
Asunto(s)
Métodos Analíticos de la Preparación de la Muestra , Moduladores de Receptores de Cannabinoides/análisis , Endocannabinoides , Espectrometría de Masas/métodos , Moduladores de Receptores de Cannabinoides/química , Precipitación Química , Humanos , MicrodiálisisRESUMEN
CB1 receptor antagonists that are peripherally restricted were targeted. Compounds with permanent charge as well as compounds that have increased polar surface area were made and tested against CB1 for binding and activity. Sulfonamide and sulfamide with high polar surface area and good activity at CB1 were rationally designed and pharmacologically tested. Further optimization of these compounds and testing could lead to the development of a new class of therapeutics to treat disorders where the CB1 receptor system has been implicated.
Asunto(s)
Moduladores de Receptores de Cannabinoides/síntesis química , Moduladores de Receptores de Cannabinoides/farmacología , Diseño de Fármacos , Descubrimiento de Drogas , Receptor Cannabinoide CB1/antagonistas & inhibidores , Miembro 1 de la Subfamilia B de Casetes de Unión a ATP/genética , Miembro 1 de la Subfamilia B de Casetes de Unión a ATP/metabolismo , Animales , Células CHO , Moduladores de Receptores de Cannabinoides/química , Moduladores de Receptores de Cannabinoides/metabolismo , Línea Celular , Cricetinae , Perros , Ligandos , Estructura Molecular , Piperidinas/metabolismo , Unión Proteica , Pirazoles/metabolismo , Ensayo de Unión Radioligante , Receptor Cannabinoide CB1/química , Rimonabant , Estereoisomerismo , Relación Estructura-Actividad , Sulfonamidas/químicaRESUMEN
Butyrylcholinesterase (BChE), a serine hydrolase biochemically related to the cholinergic enzyme Acetylcholinesterase (AChE), is found in many mammalian tissues, such as serum and central nervous system, but its physiological role is still unclear. BChE is an important human plasma esterase, where it has detoxifying roles. Furthermore, recent studies suggest that brain BChE can have a role in Alzheimer's disease (AD). The endocannabinoid arachidonoylethanolamide (anandamide) and other acylethanolamides (NAEs) are almost ubiquitary molecules and are physiologically present in many tissues, including blood and brain, where they show neuroprotective and anti-inflammatory properties. This paper demonstrates that they are uncompetitive (oleoylethanolamide and palmitoylethanolamide) or non competitive (anandamide) inhibitors of BChE (Ki in the range 1.32-7.48 nM). On the contrary, NAEs are ineffective on AChE kinetic features. On the basis of the X-ray crystallographic structure of human BChE, and by using flexible docking procedures, an hypothesis on the NAE-BChE interaction is formulated by molecular modeling studies. Our results suggest that anandamide and the other acylethanolamides studied could have a role in the modulation of the physiological actions of BChE.
Asunto(s)
Ácidos Araquidónicos/química , Butirilcolinesterasa/química , Moduladores de Receptores de Cannabinoides/química , Endocannabinoides , Alcamidas Poliinsaturadas/química , Adulto , Ácidos Araquidónicos/fisiología , Butirilcolinesterasa/sangre , Moduladores de Receptores de Cannabinoides/fisiología , Inhibidores de la Colinesterasa/química , Cristalografía por Rayos X , Humanos , Cinética , Masculino , Persona de Mediana EdadRESUMEN
We report the synthesis of new chemical probes (1a,b, 2a-c, 3a-c) based on the structure of the main endocannabinoids for their use in biological systems directly or via click chemistry. As proof of concept, 2-arachidonyl glyceryl ether based biotinylated 3b enables direct visualization of CB(1) receptor in cells. These results represent the starting point for the development of advanced small molecule chemical probes able to generate valuable information about the cannabinoid receptors.